Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs

Bioceltix files responses to EMA on BCX-CM-J: Europe's first veterinary cell-therapy drug could be authorised in Q3/Q4 2026

Bioceltix S.A. - headquartered at ul. Bierutowska 57-59 in Wrocław (postcode 51-317, Dolnośląskie voivodeship), registered in the KRS under number 0000744521 - entered Q2 2026 in the final dialogue phase with the European Medicines Agency (EMA) regarding BCX-CM-J - a mesenchymal-stem-cell drug for canine osteoarthritis. The company's responses to the final EMA list of questions are due in May 2026; the recommendation of the Committee for Veterinary Medicinal Products (CVMP) and a possible marketing authorisation could come in Q3/Q4 2026. If the procedure concludes successfully, BCX-CM-J would become the first such veterinary cell-therapy drug authorised in Europe.

It must be stressed that this is an expected, not certain scenario. Bioceltix remains a pre-commercial company: 2024 closed with PLN 0 of revenue and a net loss of PLN 14.9 m, with operating cash flow at -PLN 17.6 m. Cash at the end of 2024: PLN 33.6 m - at the current burn rate that gives the company about 18–24 months of operating runway. The entire equity value depends on materialising the registration path in 2026. Trigon DM maintained a buy rating with a price target of PLN 127.2; BM mBanku has a buy rating with a price target of PLN 110 - but these are analyst estimates, not certain market valuations.

Bioceltix

WROCŁAW · KRS 0000744521 · SPÓŁKA AKCYJNA

Revenue

0 PLN

Bierutowska 57-59: Bzdzion's 2-member board, institutional shareholder base, GPW Main Market since 2022

The address ul. Bierutowska 57-59 building III, 51-317 Wrocław places Bioceltix's seat in the industrial-laboratory cluster of northern Wrocław, near the Wrocław Technology Park. The company has operated in its current corporate form (Bioceltix S.A., KRS 0000744521) since 13 August 2018 (previously as a sp. z o.o. since 2016), and has been listed on the Warsaw Stock Exchange since 5 September 2022 - after migrating from NewConnect to the Main Market (as the 420th company on the Main Market). ISIN PLBCLTX00019.

Governance: a two-member management board (CEO Łukasz Bzdzion, also the founder - plus one board member). Shareholders are clearly institutionalised: TFI PZU 14.02%, TOTAL FIZ 8.67%, Kvarko Group ASI 8.51%, Łukasz Bzdzion 6.61% (the largest individual stake), free float around 62%. Total share capital: 5,532,253 shares.

Under Polish PKD codes the principal activity is 72.10.Z (research and development in natural and engineering sciences) - the standard code for pre-commercial biotech. The company has a registered electronic-delivery address (AE:PL-21907-79452-GJCCI-09) and the website bioceltix.com.

The product pipeline covers three main projects:

• BCX-CM-J - therapy for canine osteoarthritis (the most advanced, in final EMA dialogue).
• BCX-CM-AD - treatment of canine atopic dermatitis (AD); a pivotal study on 95 dogs (88 in the protocol) completed in 2025 showed statistically significant reduction in skin lesions by day 28, sustained to day 84. EMA submission as a line extension in Q1 2027.
• BCX-EM - treatment of joint inflammation in horses; the final EMA list of questions arrived in September 2025.

A new production plant in Wrocław is also under construction, with completion targeted for end-2026, co-financed by PARP with PLN 17.35 m.

Polish biotech sector on the WSE: Bioceltix as the only pre-commercial veterinary regenerative-medicine player

The Polish biotech sector listed on the Warsaw exchange has clear segmentation in 2026 - Bioceltix stands out as the only pre-commercial veterinary regenerative-medicine player:

• Ryvu Therapeutics (Kraków, mWIG40) - a pure pre-commercial oncology biotech with RVU120 in Phase II. Risk profile closest to Bioceltix.
• Mabion (Konstantynów Łódzki, mWIG40) - a contract biotech with the Novavax CDMO contract - post-revenue, lower risk than Bioceltix.
• Selvita - contract CRO, post-revenue, low risk profile.
• Captor Therapeutics, Celon Pharma, Medicalgorithmics - smaller biotech-pharma players in different segments.

Three structural features of the Bioceltix model that explain the valuation and risk profile:

• First European veterinary cell-therapy drug = market uniqueness - if BCX-CM-J is registered in 2026, Bioceltix would be the first entity in Europe with commercial approval for mesenchymal cell therapy in dogs. This is a meaningful structural moat, though short-lived - major veterinary-pharma players (Zoetis, Boehringer Ingelheim, Elanco) will likely respond with their own programmes. First-mover status on the European market plus PARP-co-financed production capacity make Bioceltix a candidate for potential acquisition by a global veterinary player.
• Pre-commercial = binary outcome - in 2025 the company had PLN 0 of revenue and -PLN 17.6 m of OCF. That makes the valuation entirely dependent on materialising the registration path. A positive CVMP/EMA decision = multifold share-price upside potential; a negative or 12-month-plus delay = serious valuation risk. Investors must accept this type of risk.
• Institutional shareholder base as a stabiliser, but also a potential risk - TFI PZU + TOTAL FIZ + Kvarko Group ASI together hold 31.2% of capital. Institutional funds provide operational support and access to additional financing, but can also offload stakes during share-price volatility, adding pressure to the price.

Implication for the investment profile: optionality-based valuation tied to EMA, ~2-year cash runway

The interpretation is speculative - the conclusions below are scenarios, not certainties:

“The results confirm strong anti-inflammatory activity of our product, leading to faster improvement of skin lesions in dogs.”

Three possible consequences of the 2026 phase for Bioceltix's investment profile:

• A positive EMA decision in Q3/Q4 2026 = a structural profile shift - authorising BCX-CM-J would open a European market estimated in the hundreds of millions of EUR per year. Even conservative one-year-after-launch revenue estimates (5–10% of the addressable market in the first year) suggest a revenue jump from PLN 0 to tens of millions of PLN. The Trigon target of PLN 127.2 and BM mBanku target of PLN 110 reflect this scenario.
• EMA procedure delay = an extended pre-commercial phase - a typical scenario for veterinary cell-therapy drugs: an additional CVMP question round, possible supplementary clinical data. Each 6–12 months of delay reduces the company's cash runway (from PLN 33.6 m at end-2024) and may force a share issue or debt financing.
• Negative CVMP decision = critical valuation risk - historical rejections of EU veterinary marketing authorisation applications are rare (>80% positive decisions after CVMP dialogue), but possible. In that scenario the company would have to redesign the pivotal study or change the product indication, adding 2–3 years to the schedule.

Main company-specific risks across the 2026–2027 cycle:

• EMA decision on BCX-CM-J - the key 2026 valuation catalyst; possible scenarios: positive, delay, negative.
• ~2-year cash runway - at the current burn rate (-PLN 17.6 m OCF per year) and PLN 33.6 m of cash, the company may need a share issue in 2027.
• Post-registration competition - if BCX-CM-J is approved, Zoetis and other global firms may accelerate their own programmes.
• Wrocław production plant - completion targeted for end-2026, key to commercial capacity if EMA approval comes. Construction delays may postpone the start of sales.

What you'll find in the Bioceltix S.A. profile

The Bioceltix S.A. profile in our database carries the full picture of the company: composition of the two-member management board (with founder-CEO Łukasz Bzdzion), the KRS registration history from 13 August 2018, the registered address at ul. Bierutowska 57-59 in Wrocław, e-delivery status (AE:PL-21907-79452-GJCCI-09), the website bioceltix.com, and the assigned PKD code 72.10.Z (research and development). The profile is also available in English - important for international biotech-fund investors, since Bioceltix is the only Polish pre-commercial player in veterinary regenerative medicine, with an active EMA registration path and a potential first-European-veterinary-cell-therapy-drug position.

This material is informational and does not constitute investment advice.

Data: Polish KRS Court Register (KRS 0000744521); Bioceltix S.A. - current report 27/2025 final EMA list of questions for BCX-EM (September 2025); current report on BCX-CM-AD pivotal study (2025); Stockwatch - Bioceltix pipeline analysis; Bankier - 2024 financial results; Trigon DM - buy recommendation with target price PLN 127.2; BM mBanku - buy recommendation with target price PLN 110; bioceltix.com/en/investor-relations - shareholder structure; PKD 72.10.Z classification (research and development); company history - incorporated 13 August 2018 as S.A. (previously sp. z o.o. since 2016), Main Market WSE migration 5 September 2022 (from NewConnect), as of 2026-05-02.